1. Introduction {#sec0001}
===============

Alzheimer\'s disease (AD), the most common form of dementia, is a global health concern that places an epic burden on families, caregivers, healthcare systems, and the economy. An estimated 5.6 million Americans currently live with AD, and this number is expected to increase rapidly as the number of individuals over the age of 65 increases ([@bib0025]). Brain changes, including atrophy and accumulation of β-amyloid peptide (Aβ) and tau, begin years before noticeable clinical and cognitive symptoms develop ([@bib0008]; [@bib0027]; [@bib0047]), making it imperative to investigate early risk factors that prevention methods could target to delay or prevent progression to AD.

One variable that may play a role in development of AD is obesity. Obesity is a serious and growing health concern that impacts 38.9% of U.S. adults ([@bib0022]), and is associated with numerous deleterious health conditions, including diabetes and cardiovascular disease, as well as impaired quality of life ([@bib0012]). One measure of obesity, body mass index (BMI), has a complex relationship with AD. In midlife, obesity is consistently associated with increased risk for dementia, including AD ([@bib0001]; [@bib0005]). Although the precise pathways linking obesity and neurodegenerative disease are unknown, likely mechanisms include inflammation, insulin resistance, oxidative stress, and blood-brain barrier disturbances ([@bib0002]; [@bib0038]). However, there is an "obesity paradox" when BMI is measured in older adults. There is some evidence that high BMI is associated with lower risk of developing dementia, including AD ([@bib0006]; [@bib0016]; [@bib0031]). Additionally, studies have shown that lower BMI is associated with increased AD-pathology including Aβ, total tau, and phosphorylated tau (p-tau) ([@bib0013]; [@bib0046]), and accelerated cognitive decline ([@bib0010]). Possible explanations include changes in olfaction that alter eating habits, damage to brain regions that are involved in controlling weight and food intake such as the hypothalamus and medial temporal lobe ([@bib0009]; [@bib0020]; [@bib0037]), and higher levels of leptin in obesity which may facilitate hippocampal synaptic plasticity and consequently improve learning and memory ([@bib0023]). However, the relationship between late-life BMI and AD remains to be elucidated. Higher BMI in late-life was associated with increased risk for AD ([@bib0021]), while a meta-analysis showed no relationship between late-life BMI (measured continuously) and dementia risk ([@bib0005]).

Complex phenotypes such as late-onset AD cannot fully be explained by environmental factors alone, but rather a multitude of environmental and genetic factors and their interactions. Examining moderating factors, such as genetic risk for AD, may provide additional insight into the relationship between obesity and AD. It is well-established that genetics contributes to the development of AD, and evidence suggests that late-onset AD is 60--80% heritable ([@bib0019]). Recent work suggests that polygenic risk scores for AD are better predictors of AD than are single candidate variants such as the *APOE* ε4 allele ([@bib0042]). A polygenic risk score incorporates multiple genetic variants, identified from a genome-wide association study (GWAS) of a particular trait, into a genetic propensity score for that trait. Polygenic risk for AD has also been associated with other markers of AD-related pathology, including neurofibrillary tangles, neuritic plaques, Aβ, tau, and volume loss in the hippocampus and entorhinal cortex ([@bib0011]). These results suggest that polygenic risk scores may serve as predictors of prodromal AD-related brain pathology.

The present study examined the relationship between BMI, polygenic risk for AD, and medial temporal lobe volume (entorhinal cortex and hippocampus) using the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database. Our analyses focused on these medial temporal lobe regions as they are known to be particularly vulnerable to AD ([@bib0008]), and genetic risk for AD is associated with lower volume in these regions ([@bib0011]). Additionally, given data showing that females have a greater risk of developing AD ([@bib0018]) and some evidence that the relationship between BMI and dementia risk is stronger in females ([@bib0021]; [@bib0030]), we also examined sex differences in the relationship between BMI, polygenic risk for AD, and medial temporal lobe volume. Finally, we examined the relationship between BMI, polygenic risk for AD, and other known AD-biomarkers, including Aβ, tau, and p-tau. Investigating how environmental and genetic factors interact to influence AD-related pathology has important implications for the development of specific prevention methods aimed at delaying or preventing progression to AD. These factors were examined in cognitively normal individuals in an attempt to identify early risk factors that can be targeted prior to onset of clinical symptoms.

2. Materials and methods {#sec0002}
========================

2.1. Participants {#sec0003}
-----------------

Data used in the preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). ADNI was launched in 2004 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. Additional information can be found at [www.adni-info.org](http://www.adni-info.org){#interref0002}.

The final sample included cognitively normal subjects at screening/baseline with available demographic, height and weight, polygenic hazard score (PHS), and 3T structural MRI data. Cognitively normal was defined according to ADNI\'s cognitively normal inclusion criteria, such that participants cannot have cognitive/functional impairments or memory complaints beyond what would be expected for age-related changes in memory. Additionally, participants must have normal memory function, as indicated by education-adjusted scores of at least 9 for 16 or more years of education, at least 5 for 8--15 years of education, or at least 3 for 0--7 years of education on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A) of the Wechsler Memory Scale -- Revised. Participants must also have a Mini-Mental State Examination score between 24 and 30, as well as Clinical Dementia Rating global and memory box scores of zero. Furthermore, individuals in the ADNI dataset are excluded if they have any significant neurological disease or mental health diagnoses including depression/bipolar disorder, schizophrenia, or substance abuse.

For the current study, 180 white, non-Hispanic/Latino subjects were identified to avoid population stratification effects. This sample included both accelerated (*n* = 30) and non-accelerated (*n* = 150) T1-weighted MRI scans. We restricted our analysis to the 150 subjects with non-accelerated scans, which typically have fewer image artifacts and better signal to noise ratio than accelerated scans ([@bib0026]). Of these, 20 scans failed one or more regions of the visual quality check performed by the UCSF processing team and were excluded. Three participants had two baseline scans and, in these cases, only one scan was included in our analyses. One participant had a BMI more than three standard deviations above the mean and was excluded from analyses. The final sample included 126 subjects. Four participants had diabetes. Demographics of the entire sample and as a function of BMI based on a median split are shown in [Table 1](#tbl0001){ref-type="table"}. Demographics as a function of sex are shown in Inline Supplementary Table 1. Nine of these subjects were excluded from hippocampal analyses for missing (*n* = 1) or failing (*n* = 8) the left and/or right hippocampal quality check. Sixteen of these subjects were missing tau, p-tau, and Aβ data and therefore analyses with these cerebrospinal fluid (CSF) biomarkers had a total of *n* = 110. Study procedures were approved by site-specific Institutional Review Boards and all participants and/or authorized representatives provided written informed consent consistent with the Declaration of Helsinki.Table 1Demographic and clinical characteristics.Table 1VariableTotal (*n* = 126)Low BMI (*n* = 63)High BMI (*n* = 63)*P*-ValueEffect Size[a](#tb1fn1){ref-type="table-fn"}Age in years, mean ± SD (range)74.0 ± 5.9 (63.5 -- 89.0)74.9 ± 5.9 (65.0 -- 89.0)73.0 ± 5.7 (63.5 -- 84.7)0.0710.32Males, n (%)60 (47.6)27 (42.9)33 (52.4)0.2850.095^+^Years of education, mean ± SD (range)16.5 ± 2.5 (12.0 -- 20.0)16.7 ± 2.6 (12.0 -- 20.0)16.3 ± 2.4 (12.0 -- 20.0)0.3940.15Intracranial volume, mean ± SD1,483,619 ± 150,7821,473,510 ± 145,2611,493,729 ± 156,6160.454−0.13Total geriatric depression, mean ± SD (range)0.72 ± 1.1 (0 -- 6)0.71 ± 1.0 (0 -- 5)0.73 ± 1.2 (0 -- 6)0.937−0.01Polygenic hazard score, mean ± SD (range)0.01 ± 0.7 (−1.5 -- 2.0)0.09 ± 0.7 (−1.5 -- 2.0)−0.07 ± 0.6 (−1.2 -- 1.8)0.1730.24Body mass index, mean ± SD (range)26.9 ± 3.8 (20.0 -- 36.8)23.9 ± 1.8 (20.0 -- 26.3)29.9 ± 2.7 (26.4 -- 36.8)\< 0.001[\*](#tb1fn2){ref-type="table-fn"}−2.61Entorhinal cortex volume, mean ± SD3850 ± 6093766 ± 5813935 ± 6280.118−0.28Hippocampal volume, mean ± SD7429 ± 9067329 ± 8337529 ± 9710.218−0.22[^2][^3]

2.2. Body mass index {#sec0004}
--------------------

Height (inches or centimeters) and weight (pounds or kilograms) were measured at baseline for all participants. All height values were converted to meters and all weight values were converted to kilograms. BMI was calculated using the following formula: weight (in kilograms) divided by height (in meters) squared. The sample consisted of 42 normal weight (18.5 ≤ BMI \< 25), 58 overweight (25 ≤ BMI \< 30), and 26 obese (BMI ≥ 30) participants. There were no underweight individuals (BMI \< 18.5).

2.3. MRI analysis {#sec0005}
-----------------

Participants were scanned on ADNI-approved 3T MRI scanners. T1-weighted images were acquired for each subject and pre-processed by Mayo Clinic. Automated cortical reconstruction and volumetric segmentation were performed by the University of California San Francisco with FreeSurfer image analysis suite (version 5.1), which is available for download online (<http://surfer.nmr.mgh.harvard.edu/>). The scans were processed cross-sectionally using the 2010 Desikan-Killany atlas. See supplementary material for details regarding imaging analysis with FreeSurfer.

Cortical volume values were extracted from the entorhinal cortex and hippocampus. These regions of interest were selected because they are particularly vulnerable to the early effects of AD ([@bib0008]) and are associated with genetic risk for AD ([@bib0011]). Regions of interest were registered to each individual subject\'s cortical representation via surface-based registration and cortical volume values were extracted for each subject. Values were summed across left and right hemispheres to create a bilateral volume value. Two additional FreeSurfer regions of interest, the precentral gyrus and postcentral gyrus, were selected to serve as control regions for the putative AD-vulnerable regions of interest. Intracranial volume was also extracted from the FreeSurfer analysis to serve as a covariate in analyses.

2.4. Polygenic hazard score {#sec0006}
---------------------------

Genetic risk for AD was assessed via PHS. Methods used to calculate PHS in the present study have been previously published ([@bib0011]). Briefly, 1854 AD-associated single nucleotide polymorphisms (SNPs) (at *p* \< 10^−5^) were identified using GWAS data from 17,008 AD patients and 37,154 controls in the International Genomics of Alzheimer\'s Project. Next, in a step-wise procedure, genotype data from 6409 AD patients and 9386 controls in Phase 1 of the Alzheimer\'s Disease Genetics Consortium was used to identify the top AD-associated SNPs and develop a survival model for PHS, while controlling for the effects of gender, *APOE*, and population stratification. In each step, the SNP that most improved model prediction was added, and this process continued until residuals did not improve with the addition of another SNP. In the final model, two *APOE* variants, the ε2 and ε4 alleles, and 31 AD-associated SNPs were integrated into a Cox proportional hazard model to generate a PHS that reflects an individual\'s risk for developing AD based their age and genotype. This PHS has been replicated in numerous independent samples, including Phase 2 of the Alzheimer\'s Disease Genetics Consortium, the National Institute on Aging Alzheimer\'s Disease Centers, and ADNI.

2.5. CSF biomarkers {#sec0007}
-------------------

The analyses of CSF Aβ~1-42~, tau, and p-tau~181~ were performed at the UPenn/ADNI Biomarker laboratory using the fully automated Roche Elecsys immunoassay and following a Roche Study protocol. The Elecsys Aβ CSF immunoassay is not a commercially available in vitro diagnostic assay. It is an assay that is currently under development and for investigational use only. The measuring range of the assay is 200 (lower technical limit) -- 1700 pg/mL (upper technical limit). The performance of the assay beyond the upper technical limit has not been formally established. Therefore, use of values above the upper technical limit, which are provided based on an extrapolation of the calibration curve, is restricted to exploratory research purposes and is excluded for clinical decision making or for the derivation of medical decision points. In the present study, 36 subjects had Aβ values greater than the upper technical limit, which were truncated to 1700. There were no values below the lower technical limit for Aβ or outside of the technical limits for tau (80--1300 pg/mL) or p-tau (8--120 pg/mL).

2.6. Statistical approach {#sec0008}
-------------------------

Statistical analyses were performed using IBM SPSS Statistics for Macintosh, version 25.0. Linear regression models were implemented to parse the relative effects of BMI, PHS, and covariates on AD-vulnerable regions and biomarkers. In the first model, age (years), sex, education (years), and total geriatric depression score were entered as predictors for the dependent variable of interest. For analyses examining brain volumes (entorhinal cortex, hippocampus, precentral gyrus, and postcentral gyrus), intracranial volume was also entered into the first model. In the second model, the main effects of BMI and PHS were entered. Finally, the BMI x PHS interaction term was entered into the third model. To examine sex differences in the relationship between BMI, PHS, and medial temporal lobe volume, the hippocampal and entorhinal cortex regressions were also run separately for males and females. All models also examined the contribution of cerebrovascular risk factors including hypertension, smoking history, and hypercholesterolemia/hyperlipidemia. However, these factors were not significant predictors in the model and are not reported in the final results.

3. Results {#sec0009}
==========

3.1. Entorhinal cortex {#sec0010}
----------------------

Intracranial volume, age, education, sex, and depression (model 1) accounted for 34.7% of the variance in entorhinal cortex volume. Adding PHS and BMI accounted for an additional 3.7% of the variance. Adding the BMI x PHS interaction term accounted for an additional 3.2% of the variance, which was a significant change to the model. The results suggest that the combination of greater genetic risk for AD and high BMI was associated with lower volume in the entorhinal cortex \[Δ*F*(1,117) = 6.411, *P* = 0.013, *R*^2^ = 0.416\] (See [Fig. 1](#fig0001){ref-type="fig"} and [Table 2](#tbl0002){ref-type="table"}).Fig. 1Reduced entorhinal cortex volume among subjects with high BMI and high genetic risk for AD. Values on the x-axis represent polygenic hazard scores for AD, with higher scores indicating increased risk for AD. Values on the y-axis represent standardized residuals of entorhinal cortex volume (accounting for age, sex, education, intracranial volume, and depression).Fig 1Table 2Summary of regression analysis for association with entorhinal cortex volume.Table 2VariableModel 1Model 2Model 3*BSE (B)*β*PBSE (B)*β*PBSE (B)*β*P*Age−30.0357.852−0.289\< 0.001[⁎⁎](#tb2fn2){ref-type="table-fn"}−26.0267.979−0.2510.001[⁎⁎](#tb2fn2){ref-type="table-fn"}−24.6567.821−0.2380.002[⁎⁎](#tb2fn2){ref-type="table-fn"}Sex305.340109.9370.2520.006[⁎⁎](#tb2fn2){ref-type="table-fn"}266.592109.0920.2200.016[\*](#tb2fn1){ref-type="table-fn"}259.644106.7090.2140.016[\*](#tb2fn1){ref-type="table-fn"}Education−15.95118.923−0.0650.401−14.79518.927−0.0610.436−18.42418.563−0.0760.323Intracranial volume0.0020.0000.405\< 0.001[⁎⁎](#tb2fn2){ref-type="table-fn"}0.0020.0000.411\< 0.001[⁎⁎](#tb2fn2){ref-type="table-fn"}0.0020.0000.428\< 0.001[⁎⁎](#tb2fn2){ref-type="table-fn"}Depression−15.24740.145−0.0280.705−21.85839.413−0.0410.580−53.24940.485−0.0990.191PHS−96.50267.976−0.1050.1581207.461519.2791.3120.022[\*](#tb2fn1){ref-type="table-fn"}BMI24.98912.3760.1540.046[\*](#tb2fn1){ref-type="table-fn"}15.88712.6240.0980.211BMI x PHS−49.88319.701−1.4420.013[\*](#tb2fn1){ref-type="table-fn"}R^2^0.3470.3840.416Model F12.756[⁎⁎](#tb2fn2){ref-type="table-fn"}10.494[⁎⁎](#tb2fn2){ref-type="table-fn"}10.404[⁎⁎](#tb2fn2){ref-type="table-fn"}[^4][^5][^6]

To further explore this pattern of results, partial correlations were used to examine the relationship between PHS and entorhinal cortex volume for low/high BMI groups (based on median split; *Mdn* = 26.33). Correcting for all covariates, results revealed that among individuals with high BMI, PHS was negatively correlated with entorhinal cortex volume (*pr* = −0.328, *P* = 0.012). Among individuals with low BMI, PHS was not significantly correlated with entorhinal cortex volume (*pr* = 0.018, *P* = 0.892).

Next, sex differences in the relationship between BMI, PHS, and entorhinal cortex volume were examined. The sex-stratified linear regressions revealed that the BMI x PHS interaction remained significant in females \[Δ*F*(1,58) = 5.495, *P* = 0.023, *R*^2^ = 0.320\] (See Inline Supplementary Table 2). In males, the BMI x PHS interaction was not significant \[Δ*F*(1,52) = 0.059, *P* = 0.809, *R*^2^ = 0.337\], but there was a main effect of PHS on entorhinal cortex volume (*P* = 0.039) (See Inline Supplementary Table 3).

3.2. Hippocampus {#sec0011}
----------------

Intracranial volume, age, education, sex, and depression (model 1) accounted for 40.3% of the variance in hippocampal volume. Adding PHS and BMI (model 2) accounted for an additional 1.2% of the variance, which was not significant. Adding BMI x PHS (model 3) accounted for an additional 3.5% of the variance. The BMI by PHS interaction term was significant, whereby individuals with high BMI and high PHS had reduced volume in the hippocampus \[Δ*F*(1,108) = 6.855, *P* = 0.010, *R*^2^ = 0.450\] (See [Fig. 2](#fig0002){ref-type="fig"} and [Table 3](#tbl0003){ref-type="table"}).Fig. 2Reduced hippocampal volume among subjects with high BMI and high genetic risk for AD. Values on the x-axis represent polygenic hazard scores for AD, with higher scores indicating increased risk for AD. Values on the y-axis represent standardized residuals of hippocampal volume (accounting for age, sex, education, intracranial volume, and depression).Fig 2Table 3Summary of regression analysis for association with hippocampal volume.Table 3VariableModel 1Model 2Model 3*BSE (B)*β*PBSE (B)*β*PBSE (B)*β*P*Age−61.56411.332−0.408\< 0.001[⁎⁎](#tb3fn2){ref-type="table-fn"}−58.39911.758−0.387\< 0.001[⁎⁎](#tb3fn2){ref-type="table-fn"}−56.07011.489−0.372\< 0.001[⁎⁎](#tb3fn2){ref-type="table-fn"}Sex51.758159.9930.0290.74715.997162.1960.0090.92210.418158.0220.0060.948Education−24.91527.709−0.0700.371−23.67428.262−0.0670.404−30.85227.668−0.0870.267Intracranial volume0.0030.0010.538\< 0.001[⁎⁎](#tb3fn2){ref-type="table-fn"}0.0030.0010.545\< 0.001[⁎⁎](#tb3fn2){ref-type="table-fn"}0.0030.0010.563\< 0.001[⁎⁎](#tb3fn2){ref-type="table-fn"}Depression5.16560.1360.0060.932−2.04860.260−0.0030.973−55.05862.098−0.0680.377PHS−92.95199.233−0.0700.3511852.735749.3801.3980.015[\*](#tb3fn1){ref-type="table-fn"}BMI19.00318.2330.0810.3005.87918.4550.0250.751BMI x PHS−74.38828.411−1.4960.010[\*](#tb3fn1){ref-type="table-fn"}R^2^0.4030.4150.450Model F14.984[⁎⁎](#tb3fn2){ref-type="table-fn"}11.059[⁎⁎](#tb3fn2){ref-type="table-fn"}11.053[⁎⁎](#tb3fn2){ref-type="table-fn"}[^7][^8][^9]

To further explore this pattern of results, partial correlations were conducted based on median split (*Mdn* = 26.45), as described above for the entorhinal cortex. Correcting for all covariates, results revealed that among individuals with high BMI, PHS was negatively correlated with hippocampal volume (*pr* = −0.289, *P* = 0.036). Among individuals with low BMI, PHS was not significantly correlated with hippocampal volume (*pr* = 0.125, *P* = 0.367).

Next, sex differences in the relationship between BMI, PHS, and hippocampal volume were examined. The sex-stratified linear regressions revealed that the BMI x PHS interaction remained significant in females \[Δ*F*(1,52) = 4.073, *P* = 0.049, *R*^2^ = 0.560\] (See Inline Supplementary Table 4). However, in males, age (*P* = 0.009) and intracranial volume (*P* = 0.001) were the only predictors of hippocampal volume (See Inline Supplementary Table 5).

3.3. Control regions {#sec0012}
--------------------

To investigate the specificity of BMI and PHS findings on AD-vulnerable brain regions, we examined associations in two control regions of interest. Intracranial volume, age, education, sex, and depression (model 1) accounted for 34.5% of the variance in the precentral gyrus and 40.1% of the variance in the postcentral gyrus. Adding PHS and BMI (model 2) and BMI x PHS (model 3) did not account for additional significant variance in the precentral gyrus or postcentral gyrus. Age (*P* = 0.011) and intracranial volume (*P* \< 0.001) were the only predictors of precentral gyrus volume. Intracranial volume (*P* \< 0.001) was the only predictor of postcentral gyrus volume.

3.4. CSF biomarkers {#sec0013}
-------------------

The relationship between BMI, PHS, and CSF biomarkers of AD was also explored. Results of the linear regressions revealed that the BMI x PHS interaction term did not significantly predict levels of Aβ (*P* = 0.116), tau (*P* = 0.221), or p-tau (*P* = 0.443). There was, however, a main effect of PHS on levels of Aβ (*P* \< 0.001), whereby higher PHS was associated with lower CSF levels of Aβ. This is consistent with the notion that lower CSF levels of Aβ are related to greater Aβ burden in the brain. Additionally, there was a main effect of BMI (*P* = 0.022), such that higher BMI was associated with higher tau levels. There was a marginally significant main effect of higher PHS associated with higher tau (*P* = 0.080). There were main effects of BMI (*P* = 0.028) and PHS (*P* = 0.029) on levels of p-tau, such that higher BMI and higher PHS were independently associated with higher p-tau levels.

4. Discussion {#sec0014}
=============

This study examined the associations of BMI, polygenic risk for AD, and their interaction on medial temporal lobe volume and CSF biomarkers. There were three main findings. First, results revealed that the combination of two risk factors, being overweight/obese and genetic risk for AD, was associated with lower volume in AD-vulnerable brain regions, and in particular, the entorhinal cortex and hippocampus, in cognitively normal older adults. Second, the effect was observed primarily in female participants. Finally, polygenic risk for AD and BMI independently influence levels of CSF biomarkers.

Previous work has shown inconsistent relationships between obesity and risk for AD in older adults. The findings reported here may help clarify the relationship between obesity and risk for AD by demonstrating the moderating influence of genetic risk on this relationship. In particular, high BMI may confer greater risk for neurodegenerative processes in the context of predisposing genetic risk for AD. Although the precise mechanisms that underlie the synergistic effects are unknown, it is important to note that there is substantial overlap between the metabolic consequences of obesity and the genetic pathways associated with AD. Genetic pathways of AD include immune response, lipid metabolism, cholesterol, endocytosis, cell adhesion molecules, and inflammation ([@bib0028]; [@bib0045]). Similarly, obesity is associated with inflammation, altered lipid metabolism, cholesterol, insulin resistance, and immune response ([@bib0029]; [@bib0035]; [@bib0038]). One interpretation of the findings is the deleterious metabolic cascades associated with genetic risk for AD are exacerbated with high BMI.

Results of this study also showed that the relationship between BMI and genetics on medial temporal lobe volume was pronounced in female participants. Females are more likely to develop AD than males ([@bib0004]; [@bib0015]; [@bib0018]), which cannot simply be explained by increased longevity among females ([@bib0033]). The relationship between BMI and dementia risk appears to be stronger in females than males both in mid-life and late-life, although not all studies have found sex differences ([@bib0024]; [@bib0032]). [@bib0021] showed that females with higher BMI in older adulthood had a greater risk of developing dementia. Previous research has also shown differential genetic influences in women vs. men, whereby healthy older female *APOE* ε4 carriers had the greatest risk for conversion to MCI or AD ([@bib0003]). In sub-analyses, [@bib0003] also showed that among healthy older adults, a single copy of the *APOE* ε4 allele increases risk of conversion to MCI or AD in females, but not males. A recent study also found associations between genetic risk for AD, measured both by *APOE* ε4 status and a polygenic risk score that excluded *APOE* and *TREM2*, and lower hippocampal volume in older adults, and these associations were more pronounced in females ([@bib0034]). A potential mechanism contributing to sex differences may be the role that estrogen plays in AD risk (for review, see [@bib0036]; [@bib0040]), and future studies should investigate how estrogen may interact with genetics to confer risk for AD.

The current study also examined the relationship between BMI and genetic risk for AD in two control regions of interest: the precentral gyrus and postcentral gyrus. BMI, genetic risk, and their interaction did not influence volume in the precentral gyrus or postcentral gyrus. These results suggest that the influence of BMI and genetic risk on brain volume may be specific to AD-vulnerable regions. Although atrophy is observed in normal aging, its neural signature is distinct from AD-related atrophy. The medial temporal lobe regions, including the entorhinal cortex and hippocampus, are typically the first to be impacted by AD-related cortical atrophy ([@bib0041]), however these regions are relatively spared in regards to age-related atrophy ([@bib0007]; [@bib0039]). This further supports the interpretation that the lower volume observed specifically in the medial temporal lobe regions in the present study may reflect some of the earliest AD-related pathology. As AD progresses, atrophy extends throughout the cortex, following a neuropathological trajectory similar to Braak neurofibrillary tangle staging. Cortical atrophy spreads through the temporal, parietal, and frontal regions, while sensory and motor regions are minimally impacted until late stages of the disease ([@bib0017]; [@bib0041]).

The lack of interaction between BMI and polygenic risk for AD on CSF biomarkers was surprising, as there is evidence that atrophy reflects the accumulation of Aβ, tau, and p-tau in the brain ([@bib0014]; [@bib0027]). However, there is additional evidence that MRI and CSF biomarkers may independently relate to and reflect unique parts of AD ([@bib0043]; [@bib0044]). Thus, the pathways implicated by high BMI and genetic risk may differentially impact medial temporal lobe volume and CSF biomarkers. Despite the lack of interaction, there were still independent effects of BMI and PHS on CSF biomarkers. In the present study, individuals with high genetic risk for AD had lower CSF Aβ (reflecting greater intracranial Aβ burden), higher p-tau, and marginally higher tau, which is consistent with previous research showing that higher PHS is associated with greater AD-related pathology ([@bib0011]). Furthermore, higher BMI was associated with greater levels of tau and p-tau, suggesting that high BMI in late-life may be a risk factor for AD.

This study has several limitations that should be considered. First, although this study observed AD-related vulnerabilities using MRI biomarkers, it cannot be determined whether any of the individuals in this study will develop AD in the future. Additionally, ADNI does not collect data on BMI prior to the baseline assessment, and thus the influence of lifetime BMI on the relationship between late-life BMI, genetic risk for AD, and AD-related biomarkers could not be examined. Investigating the relationship between AD-related pathology, BMI, and polygenic risk for AD longitudinally can further elucidate how these variables interact to influence the progression of AD. Furthermore, the sample did not include any individuals with a BMI below 20 and thus the relationship between underweight BMI, genetics, and AD-related biomarkers could not be examined. However, this relationship should be investigated, as previous research has shown that having a BMI below 20 in older adulthood may increase risk for dementia ([@bib0016]). Another limitation is the selectivity of the sample. The findings of this study may not generalize to ethnic groups other than white, non-Hispanic/Latino older adults. Additional work is necessary to determine how BMI and genetic risk for AD interact in other samples.

5. Conclusions {#sec0015}
==============

This study reports that the combination of high BMI and high genetic risk for AD is associated with lower volume in the medial temporal lobe, and this relationship is more pronounced in females. Additionally, high BMI and high genetic risk are independently associated with increased CSF biomarker burden. These results underscore the importance of examining the synergistic effects of genetic and environmental risk factors on markers of AD, with the overarching goal of developing methods aimed at delaying or preventing progression to AD.
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Supplementary material contains additional details regarding MRI analysis with FreeSurfer.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf){#interref0001}

[^2]: Reported effect sizes are Cohen\'s *d* unless otherwise indicated. +Reported effect size is phi correlation coefficient because variable is binary.

[^3]: *P* \< 0.05.

[^4]: PHS = polygenic hazard score; BMI = body mass index.

[^5]: *P* \< 0.05.

[^6]: *P* \< 0.01.

[^7]: PHS = polygenic hazard score; BMI = body mass index.

[^8]: *P* \< 0.05.

[^9]: *P* \< 0.01.
